To provide long-term capital appreciation and income.
Name | % Net Assets |
---|---|
GlaxoSmithKline | 7.7% |
HSBC Holdings PLC (UK Reg) | 7.3% |
Astrazeneca | 6.8% |
BG GROUP | 6.7% |
UNILEVER | 5.0% |
ROYAL DUTCH SHELL B | 4.1% |
Booker Group | 3.9% |
William Morrison Supermarkets | 3.4% |
Compass Group | 3.0% |
Centrica | 2.9% |
Key | % Net Assets |
---|---|
GlaxoSmithKline | 7.7% |
HSBC Holdings PLC (UK Reg) | 7.3% |
Astrazeneca | 6.8% |
BG GROUP | 6.7% |
Other | 71.5% |
Date | n/a |
---|---|
Bid | 0.00 |
Offer | 0.00 |
Currency | n/a |
Change | 0.00 |
% | n/a |
YTD change | 0.00 |
YTD % | n/a |
Fund Inception | 01/09/1968 |
---|---|
Fund Manager | Richard Colwell |
TER | 1.63 (15-Apr-2012) |
Minimum Investment | |
---|---|
Initial | 1000 |
Additional | n/a |
Savings | 50 |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.12 |
You are here: research